Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06207799
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 100
- Registration Number
- NCT06188676
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Zhongnan Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05970185
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 200
- Registration Number
- NCT05931718
- Locations
- 🇮🇹
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Target Recruit Count
- 66
- Registration Number
- NCT05840640
- Locations
- 🇮🇳
Dept of Hepatology, PGIMER, Chandigarh, India
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05799612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis with Decitabine Combined with Filgrastim for Children and Young Adults with AML, MDS and Related Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Franziska Wachter
- Target Recruit Count
- 37
- Registration Number
- NCT05796570
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 377
- Registration Number
- NCT05722015
- Locations
- 🇭🇺
Törökbálinti Tüdőgyógyintézet ( Site 2105), Törökbálint, Pest, Hungary
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207), Kaohsiung, Taiwan
🇺🇸St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023), Phoenix, Arizona, United States
Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Andrews Research & Education Foundation
- Target Recruit Count
- 10
- Registration Number
- NCT05573386
- Locations
- 🇺🇸
Andrews Research and Education Foundation, Gulf Breeze, Florida, United States
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05561751
- Locations
- 🇺🇸
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Florida (UF) - Shands Cancer Center, Gainesville, Florida, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.